A single platelet aggregometric assay for pro-and antiaggregatory prostanoids

Area of Science:

• Biochemistry
• Pharmacology
• Thrombosis Research

Background:

• Prostanoids play a dual role in platelet aggregation, acting as either disaggregatory or proaggregatory agents.
• Characterizing these opposing effects in a single assay is crucial for understanding thrombosis and developing antiplatelet therapies.

Purpose of the Study:

• To develop and validate a novel "post-addition assay" for simultaneously assessing disaggregatory and proaggregatory prostanoids.
• To evaluate the relative potencies of various prostanoids in influencing platelet aggregation.

Main Methods:

• A "post-addition assay" was employed, involving the addition of test agents to platelet-rich plasma (PRP) containing prostacyclin (PGI2) 90 seconds after an adenosine diphosphate (ADP) challenge.
• Relative potencies of known ADP-induced aggregation inhibitors were compared with disaggregatory potencies from the post-addition assay.
• Proaggregatory relative potencies of specific prostanoids, including 16,16-dimethyl-PGE2, PGE2, PGH2, and an epoxymethano-prostadienoic acid analog, were determined.

Main Results:

• The relative potencies of established inhibitors of ADP-induced platelet aggregation correlated directly with their determined disaggregatory potencies in the post-addition assay.
• The proaggregatory relative potencies were determined as follows: 16,16-dimethyl-PGE2 (5.8) : PGE2 (2) : PGH2 (1.8) : 11α,9α-epoxymethano-15α-hydroxy-prostadienoic acid (1).
• These findings highlight the substantial thrombosis-promoting activity of PGE2 and its derivatives.

Conclusions:

• The developed post-addition assay is effective for simultaneously characterizing both disaggregatory and proaggregatory prostanoids.
• Prostaglandin E2 (PGE2) and its analogs exhibit significant prothrombotic potential, warranting further investigation in the context of cardiovascular disease.